TY  - GEN
AU  - Maio,Michele
AU  - Scherpereel,Arnaud
AU  - Calabrò,Luana
AU  - Aerts,Joachim
AU  - Perez,Susana Cedres
AU  - Bearz,Alessandra
AU  - Nackaerts,Kristiaan
AU  - Fennell,Dean A
AU  - Kowalski,Dariusz
AU  - Tsao,Anne S
AU  - Taylor,Paul
AU  - Grosso,Federica
AU  - Antonia,Scott J
AU  - Nowak,Anna K
AU  - Taboada,Maria
AU  - Puglisi,Martina
AU  - Stockman,Paul K
AU  - Kindler,Hedy L
TI  - Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
SN  - 1474-5488
PY  - 2017///0925
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - therapeutic use
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Agents
KW  - Disease-Free Survival
KW  - Double-Blind Method
KW  - Female
KW  - Humans
KW  - Lung Neoplasms
KW  - drug therapy
KW  - Male
KW  - Mesothelioma
KW  - Mesothelioma, Malignant
KW  - Middle Aged
KW  - Response Evaluation Criteria in Solid Tumors
KW  - Survival Rate
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
UR  - https://doi.org/10.1016/S1470-2045(17)30446-1
ER  -